Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | F3 | P13726 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744147 | 1.00 | CYP3A4 (0.61) | CYP3A4PTPN1RELACYP1A2MEN1 | |
| SCHEMBL29966677 | 0.86 | RELA (0.62) | CYP3A4PTPN1RELACYP1A2MEN1 | |
| SCHEMBL29462468 | 0.86 | RELA (0.62) | CYP3A4PTPN1RELACYP1A2MEN1 | |
| SCHEMBL6552210 | 0.86 | RELA (0.62) | CYP3A4PTPN1RELACYP1A2MEN1 | |
| SCHEMBL78427 | 0.86 | RELA (0.62) | CYP3A4PTPN1RELACYP1A2MEN1 | |
| SCHEMBL78426 | 0.86 | RELA (0.62) | CYP3A4PTPN1RELACYP1A2MEN1 | |
| SCHEMBL1149654 | 0.85 | PTPN1 (0.58) | CYP3A4PTPN1RELACYP1A2MEN1 | |
| SCHEMBL1380884 | 0.85 | CYP3A4 (0.62) | CYP3A4PTPN1RELACYP1A2MEN1 | |
| SCHEMBL16198413 | 0.85 | APP (0.69) | CYP3A4PTPN1RELACYP1A2MEN1 | |
| SCHEMBL16198414 | 0.85 | APP (0.69) | CYP3A4PTPN1RELACYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | claimed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | claimed |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | disclosed |
| EP-3803402-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2023-04-26 | — | — | EP | disclosed |
| EP-3578981-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-20210231661-A1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2021-07-29 | — | — | US | disclosed |
| EP-3803402-A1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | Tudag Tu Dresden Aktiengesellschaft (DE) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019233779-A1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | Technische Universität Dresden (DE) | 2019-12-12 | — | — | WO | disclosed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC UNM (US) | 2016-02-11 | — | — | US | disclosed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007059155-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
| US-RE29358-E | ANTI-MALARIA AND ANTI-TUBERCULOSIS AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | MYC, CCNE2, CCNE1 | CYP3A4 2309/4885PTPN1 3556/4885RELA 102/4885 |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | CYP3A4 3155/4885PTPN1 4773/4885RELA 258/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | CYP3A4 3155/4885PTPN1 4773/4885RELA 258/4885 |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | CYP3A4 783/4885PTPN1 1234/4885RELA 2172/4885 |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | CYP3A4 783/4885PTPN1 1234/4885RELA 2172/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | CYP3A4 936/4885PTPN1 4300/4885RELA 88/4885 |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | CYP3A4 171/4885PTPN1 2888/4885RELA 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.